ImmunityBio (NASDAQ:IBRX) Trading 8.3% Higher – Still a Buy?

Posted by Francis Steltz on Jun 26th, 2026

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) was up 8.3% during trading on Friday . The company traded as high as $8.43 and last traded at $8.4350. 6,283,108 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 26,390,656 shares. The stock had previously closed at $7.79.

Analyst Ratings Changes

IBRX has been the subject of a number of research reports. BTIG Research reissued a “buy” rating and issued a $12.00 price target on shares of ImmunityBio in a research report on Thursday, May 21st. Piper Sandler reissued an “overweight” rating and issued a $12.00 target price (up from $7.00) on shares of ImmunityBio in a research report on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of ImmunityBio in a research report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, April 14th. Finally, D. Boral Capital reissued a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a report on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $14.20.

Check Out Our Latest Research Report on IBRX

ImmunityBio Stock Up 10.8%

The stock has a market cap of $9.04 billion, a PE ratio of -10.33 and a beta of 0.03. The stock has a fifty day moving average of $7.56 and a 200-day moving average of $6.48.

ImmunityBio (NASDAQ:IBRX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The business had revenue of $44.21 million during the quarter, compared to analysts’ expectations of $43.07 million. Equities research analysts forecast that ImmunityBio, Inc. will post -0.31 earnings per share for the current fiscal year.

Insider Activity at ImmunityBio

In other news, Director Barry J. Simon sold 23,033 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $7.18, for a total transaction of $165,376.94. Following the completion of the sale, the director owned 2,827,788 shares in the company, valued at $20,303,517.84. This represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On ImmunityBio

A number of large investors have recently bought and sold shares of IBRX. Vanguard Group Inc. boosted its holdings in shares of ImmunityBio by 18.5% in the fourth quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock valued at $64,899,000 after acquiring an additional 5,122,052 shares in the last quarter. State Street Corp lifted its position in ImmunityBio by 45.4% in the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after purchasing an additional 5,139,890 shares during the period. Geode Capital Management LLC increased its position in ImmunityBio by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock worth $15,684,000 after purchasing an additional 1,030,113 shares during the period. Heights Capital Management Inc. purchased a new position in shares of ImmunityBio during the 3rd quarter worth approximately $16,152,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of ImmunityBio by 439.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after buying an additional 5,012,001 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

(Get Free Report)

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.